DBT Bureau
Pune, 28 Nov 2025
| Date | Closing Price (₹) |
|---|---|
| 14-Nov-2025 | 812.65 |
| 17-Nov-2025 | 820.90 |
| 18-Nov-2025 | 814.55 |
| 19-Nov-2025 | 830.15 |
| 20-Nov-2025 | 869.30 |
| 21-Nov-2025 | 864.80 |
| 24-Nov-2025 | 841.25 |
| 25-Nov-2025 | 834.00 |
| 26-Nov-2025 | 927.40 |
| 27-Nov-2025 | 882.75 |
NATCO records ₹1,463 crore consolidated revenue and ₹517.9 crore of profit after tax for Q2FY26
NATCO recorded consolidated total revenue of INR 1,463.0 Crore for the quarter ended on 30th September 2025 as against INR 1,434.9 crore as of 30th September 2024. EBITDA (including other income) for the quarter was at INR 679.2 Crore with margins at 46.4%. The net profit for the period, on a consolidated basis was INR 517.9 Crore.
During the quarter, the Company has incurred substantial R&D expenses on bioequivalence and one-time employee bonus, in addition to other business-related provisions.
The Board of Directors have declared an interim dividend of INR 1.5 per equity share of INR 2 each during Q2FY26.
Segmental Revenue Split (INR Crore)
| Segment | Q2FY26 | Q1FY26 | Q2FY25 |
| Active Pharmaceutical Ingredients (API) | 53.9 | 52.6 | 49.6 |
| Domestic Formulations | 105.4 | 107.0 | 102.3 |
| Formulations export (Incl. profit share and subs) | 1,147.0 | 1,126.5 | 1,211.3 |
| Crop Health Sciences (CHS) | 52.4 | 34.7 | 14.1 |
| Other operating and non-operating income | 104.3 | 69.8 | 57.6 |
| Total | 1,463.0 | 1,390.6 | 1,434.9 |
